atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
The patients who watched the personalized AI avatar videos showed better understanding of their treatment plan, a greater ability to engage with health care decisions, and reduced stress compared to those who watched the standard educational video.
Read more here.
Once cancer has begun to spread within the body (metastasise) it generally becomes harder to treat and survival rates are lower. The new research focuses on patients with oligometastatic breast cancer, meaning a few small secondary tumors have broken away…
Attendees
Sponsors and Exhibitors
Contact us